Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1558-1566

[No Author Info available]

Author keywords

Bactericidal activity; Early bactericidal activity; Pharmacokinetics; Phase 2; Safety; Treatment; Tuberculosis

Indexed keywords

N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PLACEBO; RIFAMPICIN; ADAMANTANE; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMMON COLD; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MONOTHERAPY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; SOFT TISSUE DISEASE; SPUTUM CULTURE; TREATMENT DURATION; VISUAL IMPAIRMENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADAMANTANE; ADULT; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; ETHYLENEDIAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929745288     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku553     Document Type: Article

References (31)

1. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
2. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1797-809.
3. Li K, Schurig-Briccio LA, Feng X et al. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014; 57: 3126-39.
4. Ministry of Health and Social Welfare, Republic of South Africa. National Tuberculosis Management Guidelines, 2008. http://www.who.int/hiv/pub/ guidelines/south_africa_tb.pdf.
5. Sacksteder KA, Protopopova M, Barry CE 3rd et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 2012; 7: 823-37.
6. Chen P, Gearhart J, Protopopova M et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006; 58: 332-7.
7. Reddy VM, Dubuisson T, Einck L et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67:1163-6.
8. Reddy VM, Einck L, Andries K et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-6.
9. Nikonenko BV, Protopopova M, Samala R et al. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51: 1563-5.
10. Jia L, Noker PE, Coward L et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006; 147: 476-85.
11. Jia L, Tomaszewski JE, Hanrahan C et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144: 80-7.
12. Niemi M, Backman JT, Fromm MF et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
13. Kanebratt KP, Diczfalusy U, Backstrom T et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4b-hydroxycholesterol. Clin Pharmacol Ther 2008; 84: 589-94.
14. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-7.
15. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations:a randomised trial. Lancet 2012; 380: 986-93.
16. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-5.
17. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-54.
18. US Food and Drug Administration. Guidance for Industry: Pulmonary Tuberculosis: Developing Drugs for Treatment. Draft Guidance. November 2014. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM373580.pdf.
19. European Medicines Agency. ICH Topic E14: The Clinical Evaluation of QT/QTc Interval prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. November 2005. http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/09/WC500002879. pdf.
20. Ruslami R, Nijland HM, Alisjahbana B et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007; 51: 2546-51.
21. Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003; 1: 141-55.
22. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010; 16: 204-19.
23. Yu KS, Yim DS, Cho JY et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69: 266-73.
24. Hamelin BA, Bouayad A, Methot J et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67: 466-77.
25. Jindani A, Aber VR, Edwards EA et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
26. Kayigire XA, Friedrich SO, Venter A et al. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol 2013; 51:1894-8.
27. Wallis RS, Jakubiec W, Mitton-Fry M et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012; 7: e30479.
28. Hoff DR, Ryan GJ, Driver ER et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 2011; 6:e17550.
29. Driver ER, Ryan GJ, Hoff DR et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3181-95.
30. Kramnik I, Dietrich WF, Demant P et al. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97: 8560-5.
31. National Cancer Institute. Common Terminology Criteria for Adverse Events, v4.0. NCI, NIH, DHHS. 29 May 2009. NIH publication #09-7473.